The rise of antibiotic-resistant superbugs continues to pose an escalating threat to public health worldwide, as researchers and medical practitioners scramble to find new alternatives to ineffective antibiotic treatments. In response to this issue, researchers and thoughts leaders from the University of North Texas Health Science Center (UNTHSC) will join a host of biotech industry leaders and preeminent infectious disease researchers from around the world at the 16th annual conference on Superbugs & Superdrugs, which will be held in London on 5th and 6th March. The theme this year will seek to tackle the issue of the global threat of antibacterial resistance head on.
Over the past decade, the conference has quickly established itself as a premier event in its field due to its ability to bring together major pharmaceutical companies, academia, senior scientists and KOLS involved in PPP funding, regulation, infectious disease, antimicrobial research and public health — all critical elements of addressing the need for a critical pivot in dealing with the onset of superbugs. This year, conference is in such demand that conference organizers are planning on closing registrations this week.
In addition to UNTHSC, the following biotech and life sciences organizations will be attending and participating in the conference: Anacor Pharmaceuticals, Astellas Pharma Europe, Basilea Pharmaceutica , Biomedical Advanced Research and Development Authority, Brandenburg Antiinfektiva GmbH and Forschungszentrum Borstel, Cubist Pharmaceuticals, DSTL Chemical And Biological Sciences, Da Volterra, Debiopharm SA, EFPIA, Euprotec, European Commision, F. Hoffmann-La Roche, Ferrer Internacional, Genentech, Grifols America, GSK, Idenix Laboratories, Johnson and Johnson, Kings College University, KWS BioTest, MedImmune, Melinta Therapeutics, MHRA, NDA Group, Nosopharm, Office for Health Economics, PharmaConsulting, Phico Therapeutics, Polyphor, Procarta Biosystems, Roche Consumer Health, Sanofi-Aventis, SeaLife Pharma GmbH, Selcia, St George’s Hospital Medical School, The Wellcome Trust, Tiber Creek Partners, TranScrip Partners, PreClinical Services, Valoralia, and many more.
UNTHSC is not the only Texas story at this year’s conference. In addition, there will be a major update on the GSK and BARDA $200 million antibiotic collaboration that is being ramped up at Texas A&M University’s College Station campus. BioNews Texas contributing Editor Charles Moore reported in a previous article on how the Texas A&M/GlaxoSmithKline Influenza-Vaccines Facility will position Texas at the forefront of fighting a potential flu pandemic in the United States.
Conference speaker Dr Michael Mourez, Therapeutic Area Leader from Sanofi commented on the critical importance of this year’s conference: “I think it is clear that there is a paradigm shift in the way Pharma companies are tackling antimicrobial research. The funding of the studies and the stance of the regulatory agencies are changing and the Pharma are responding to this by embracing these new opportunities as well as by promoting innovative approaches. This conference will bring together these different angles: market, funding and pharma to provide insights. This is a unique opportunity to keep abreast of an ‘old’ field that is dramatically challenged and forced to adapt fast.”
The conference will also feature “an address on the EU action plan presented by the Head of Infectious Disease and Public Heath from the European Commission, and a panel debate on funding antibiotic research and an interactive workshop on preventing resistance in 2014 with a focus on gram negative bacteria and antibiotic stewardship.”